Speaker illustration

Doctor Mark Kowala

Zionsville (United States of America)

Member of:

European Society of Cardiology

A PhD scientist with expertise in Cardiovascular Disease, Drug Discovery, Translational Medicine, Early Clinical Development. Proficient in heart failure, cardiomyopathy, dyslipidemia, atherosclerosis, and hypertension. Discovered and developed small molecule, peptide, monoclonal antibody therapeutics, several of which are in clinical development or FDA approved. Has 30 years of experience in the Pharmaceutical Industry as a scientist and as a leader of scientists. Hobbies include travel to historic locations and hiking.

Long-acting CRF2 receptor agonist COR-1389 improves cardiopulmonary function parameters in monocrotaline-induced pulmonary hypertension and right heart failure rat model

Event: ESC Congress 2024

Topic: Pharmacotherapy

Session: Heart failure: bench to bedside

Thumbnail